厦门综改区社会管理创新的实践及其特色

创新社会管理是厦门全面实施综合配套改革试验的重要内容。本文探索厦门实施综合配套改革试验区在基层社区治理、基层公共服务、社会志愿参与、社会组织管理、涉台事务治理等五大领域的创新实践,总结其创新经验及特色。作者认为厦门综合配套改革试验区已经初步探索出一条以民生优先、协同治理、制度创新、技术支撑为特征的社会管理创新之路,逐步形成政府与其它社会主体协同创新的社会管理新模式。厦门大学985工程公共管理重点学科建设项目; 福建省2012年度社科规划重点项目“推进厦门综合配套改革试验区社会管理体制创新研究”(项目编号:2012A015

Continuous electrodeposition for lightweight, highly conducting and strong carbon nanotube-copper composite fibers

Carbon nanotube (CNT) fiber is a promising candidate for lightweight cables. The introduction of metal particles on a CNT fiber can effectively improve its electrical conductivity. However, the decrease in strength is observed in CNT-metal composite fibers. Here we demonstrate a continuous process, which combines fiber spinning, CNT anodization and metal deposition, to fabricate lightweight and high-strength CNT-Cu fibers with metal-like conductivities. The composite fiber with anodized CNTs exhibits a conductivity of 4.08 x 10(4)-1.84 x 10(5) S cm(-1) and a mass density of 1.87-3.08 g cm(-3), as the Cu thickness is changed from 1 to 3 mu m. It can be 600-811 MPa in strength, as strong as the un-anodized pure CNT fiber (656 MPa). We also find that during the tensile tests there are slips between the inner CNTs and the outer Cu layer, leading to the drops in electrical conductivity. Therefore, there is an effective fiber strength before which the Cu layer is robust. Due to the improved interfacial bonding between the Cu layer and the anodized CNT surfaces, such effective strength is still high, up to 490-570 MPa

中国被子植物濒危等级的评估

本文基于文献和标本信息收集以及专家提供的数据,运用IUCN濒危物种红色名录方法首次对中国范围内所有已知被子植物进行灭绝风险评估。结果显示,在评估的30,068种被子植物中,灭绝等级(含灭绝、野外灭绝、地区灭绝)共计40种;受威胁等级(极危、濒危、易危)3,363种,受威胁比例为11.18%。从空间分布看,我国受威胁被子植物主要集中分布在西南地区以及台湾、海南等岛屿,且主要分布在中低海拔地区。对受威胁物种的分析结果表明,包括原生植被破坏在内的生境丧失及破碎化是我国被子植物濒危的首要因子,涉及约84.1%的受威胁物种;过度采挖和物种内在系统问题位列致危因子的第二、三位,分别涉及38%和14%的物种。其他的致危因子包括外来入侵种在内的种间竞争、环境污染、自然灾害和全球气候变化等。一个物种的致危因子往往是多方面的。本次评估与2004年红色名录相比,生境变化、实施保护措施及分类学新修订使一些物种的濒危等级发生了变化,这也印证了红色名录是一个动态的系统,需要根据最新信息进行更新,以便为生物多样性保护提供实时准确的基础数据

中国高等植物受威胁物种名录

2008年,环境保护部和中国科学院联合启动了《中国生物多样性红色名录——高等植物卷》的编制工作。通过这项工作,我们依据IUCN濒危物种红色名录标准对中国野生高等植物的濒危状况进行了全面评估,编制了中国高等植物红色名录。2013年9月,该名录以环境保护部、中国科学院第54号公告形式发布,即《中国生物多样性红色名录—

新疆准噶尔北缘玉勒肯哈腊苏铜(钼)矿床流体包裹体和稳定同位素研究/Fluid inclusion and stable isotope study of Yulekenhalasu copper-(molybdenum) deposit in northern margin of Junggar, Xinjiang[J]

玉勒肯哈腊苏中型斑岩型铜(钼)矿主要赋存在闪长玢岩中,有少量矿化产在北塔山组火山岩及似斑状黑云母石英二长岩中.矿化呈细脉状、细脉-浸染状和浸染状.围岩蚀变主要为钾化、硅化、绢云母化、石膏化、磁铁矿化、绿泥石化、绿帘石化.矿床的形成经历了斑岩期、剪切变形期和表生期,铜和钼矿化主要形成于斑岩期的硫化物-钾硅酸盐阶段和辉钼矿阶段.石英和方解石中的流体包裹体可划分为H2 O-NaCl型和H2O-CO2(±CH4 /N2)-NaCl型.硫化物-钾硅酸盐阶段的成矿温度为141～500℃,主要集中在200～340℃;流体的ω(NaCleq)为2.96％～14.97％;流体的密度为0.60～ 0.98 g/cm3.碳酸盐阶段的流体以中-低温度(140～320℃)和低盐度[ω(NaCleq)为2.74％～10.61％]为特征.硫化物的δ34S值集中于-4.5‰～0.1‰,峰值为-3.5‰,表明硫来自深源岩浆.石英和方解石的δ18OSMOW值为9.1‰～13.2‰oo,δ18OH2O值为2.05‰～6.28‰,δD值为-120‰～ 97‰,表明主成矿阶段的成矿流体主要是岩浆水,混合有大气降水;碳酸盐阶段的流体主要为大气降水,混合有岩浆水.成矿时代为中泥盆世[(373.9±2.2 Ma)],成矿作用与闪长玢岩的侵入有关.温度和压力的降低导致流体沸腾,同时,水-岩交换反应、流体成分的改变等在铜钼成矿过程中起着主导作用

新疆准噶尔北缘玉勒肯哈腊苏铜(钼)矿区韧性剪切变形时代——来自白云母和黑云母Ar-Ar年龄的约束/Ar-Ar Dating of the Ductile Shear Zones in the Yulekenhalasu Cu-(Mo) Ore Deposit[J]

玉勒肯哈腊苏斑岩铜(钼)矿主要赋存于闪长玢岩中,少量在北塔山组火山岩及似斑状石英二长岩中.矿化呈细脉状、细脉-浸染状和浸染状.成矿过程经历了斑岩期、剪切变形期和表生期.矿区发育韧性剪切变形带,中泥盆统北塔山组、下石炭统姜巴斯套组、岩体及矿体均发生了剪切变形作用.沿剪切面发育黑云母和白云母新生矿物.白云母的坪年龄和等时线年龄分别为283.8±1.5 Ma和285.4±3.1 Ma,黑云母的坪年龄和等时线年龄分别为277.0±2.0 Ma和277.0±4.0 Ma,在误差范围内基本一致,限定矿区韧性剪切变形时间在早二叠世(284 ～277 Ma),与区域额尔齐斯-玛因鄂博断裂活动时间一致.主要成矿作用形成于斑岩期,成矿时代为中泥盆世(374 Ma),早二叠世的韧性剪切变形作用只对铜(钼)矿化进行改造

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials